To this end, the CD103+CD8+ TRM cells detected at the tumor stroma and margin, as well as within the tumor epithelia, expressed markers of tumor-killing activity, which may represent anti-tumor responses of TRM cells targeting autologous CRLM-derived tumors with unsurmountable growth capacity. The gene discussed is CD8A; the disease is neoplasm.